Core Viewpoint - The strategic collaboration between Innovent Biologics and Eli Lilly aims to advance the global research and development of innovative drugs in oncology and immunology, marking a significant milestone in their long-term partnership [1] Group 1: Financial Aspects - Innovent Biologics received an upfront payment of $350 million as part of the agreement [1] - The company is eligible for up to approximately $8.5 billion in milestone payments related to research, regulatory, and commercialization achievements [1] - Innovent Biologics retains the rights to all products in Greater China while Eli Lilly secures exclusive global development and commercialization rights outside this region [1] Group 2: Strategic Collaboration - This agreement represents the seventh collaboration between Innovent Biologics and Eli Lilly, further deepening their productive partnership [1] - The collaboration leverages Innovent's established antibody technology platform and efficient clinical capabilities to lead projects from drug discovery to clinical concept verification in China [1] - Eli Lilly will benefit from the global exclusive development and commercialization rights for the relevant projects outside Greater China [1]
信达生物高开逾4% 与礼来制药达成战略合作 潜在交易额高达88.5亿美元